Methods for treating atrial fibrillations with budiodarone

Extended heart rhythm monitoring and iterative dosage adjustment with wearables help qualify patients for pharmacotherapy, effectively reducing AFib burden and stroke risk, addressing the limitations of current AFib treatments.

WO2025010071A1PCT designated stage expired Publication Date: 2025-01-09XYRA LLC
View PDF 5 Cites 2 Cited by

Patent Information

Application Number
PCT/US2023/027521
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-05
Filing Date
2023-07-12
Publication Date
2025-01-09

Smart Images

  • Figure US2023027521_09012025_PF_FP_ABST
    Figure US2023027521_09012025_PF_FP_ABST
Patent Text Reader

Abstract

Patients with either paroxysmal or persistent AFib and whose untreated AFib is greater than a threshold level of AFib are qualified as eligible for treatment with a drug, (e.g., budiodarone) capable of controlling heart rhythm in the patient. Qualified patients are treated with the drug while their heart rates are monitored with a wearable, and if a given dose of the drug is deemed ineffective, the dose is adjusted until an effective dose is determined for the patient of the patient is deemed non-responsive to the drug and removed from therapy.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods for treating atrial fibrillation

    US9549912B2

  • Methods for treating atrial fibrillation

    US20170354635A1

  • Methods for treating atrial fibrillations

    US20230372284A1

  • Budiodarone formulations

    WO2014143625A1

  • Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations

    WO2023133510A1

Cited By

  • Methods for reducing the risk of heart failure or strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations

    US12551706B2

  • Formulations of crystalline budiodarone Form-1

    US12773398B1